<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05011981</url>
  </required_header>
  <id_info>
    <org_study_id>Hemo-LAAO</org_study_id>
    <nct_id>NCT05011981</nct_id>
  </id_info>
  <brief_title>Hemostatic Activity Following LAAO</brief_title>
  <official_title>Hemostatic Activity Following Left Atrial Appendage Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to prospectively investigate hemostatic activity&#xD;
      following transcatheter left atrial appendage occlusion (LAAO).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective cohort study of patients undergoing transcatheter LAAO at Aarhus&#xD;
      University Hospital. Hemostatic consequences following device implantation will be evaluated&#xD;
      using blood samples collected pre- and post-procedurally, and serially during three months&#xD;
      follow-up in 135 LAAO patients. Platelet function and characteristics, overall activation of&#xD;
      the extrinsic coagulation pathway and the intrinsic contact activation pathway, as well as&#xD;
      endothelial response to implantation, will be assessed through a wide range of biochemical&#xD;
      analyses. Patients will serve as their own controls, with a final control blood sample&#xD;
      collected at three-months follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in coagulation activity</measure>
    <time_frame>7 days, 14 days, 90 days</time_frame>
    <description>Coagulation activity as measured by prothrombin fragment 1+2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in platelet activity</measure>
    <time_frame>7 days, 14 days, 90 days</time_frame>
    <description>Incl. platelet count, turnover, and aggregation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional measures of changes in coagulation and contact activation</measure>
    <time_frame>7 days, 14 days, 90 days</time_frame>
    <description>Incl. thrombin generation, fibrinogen, d-dimer and coagulation factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in endothelial activation and response</measure>
    <time_frame>7 days, 14 days, 90 days</time_frame>
    <description>Incl. changes in soluble thrombomodulin, syndecan-1, selectin and von Willebrand factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-procedural bleeding events</measure>
    <time_frame>7 days, 14 days, 90 days</time_frame>
    <description>As defined by the Bleeding Academic Research Consortium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographical evidence of device endothelization</measure>
    <time_frame>7 days, 14 days, 90 days</time_frame>
    <description>On CT indicated by no contrast patency distal to the LAAO device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographically confirmed device-related thrombosis</measure>
    <time_frame>7 days, 14 days, 90 days</time_frame>
    <description>Defined as high grade HAT on follow-up cardiac CT or TEE</description>
  </secondary_outcome>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Left Atrial Appendage Occlusion</intervention_name>
    <description>Interventional left atrial appendage occlusion with the Amulet or Watchman device</description>
    <other_name>Left Atrial Appendage Closure</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Only patients already eligible for LAAO will be screened by clinical personnel and&#xD;
        potentially recruited for participation. Blood samples will be systematically sampled&#xD;
        during planned follow-up timepoints.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Atrial fibrillation (paroxysmal, persistent, or permanent)&#xD;
&#xD;
          -  Admitted and eligible for LAAO&#xD;
&#xD;
          -  Signed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hereditary bleeding disorders (i.e. Hemophilia A and B, Von Willebrand disease)&#xD;
&#xD;
          -  Platelet count &lt; 75 x 109/ml&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Anders Kramer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital, Aarhus, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anders Kramer, MD</last_name>
    <phone>+45 7845 2262</phone>
    <email>anha@clin.au.dk</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

